Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
The company develops, manufactures, and markets pharmaceutical products in India, the United States, Latin America, Europe, and internationally. The company provides branded and generic formulations in therapeutic areas of dermatology, respiratory, and oncology.
Glenmark Pharmaceuticals Limited, is a listed public company incorporated on 18 November, 1977. It is classified as a public limited company and is located in , . It's authorized share capital is INR 277.00 cr and the total paid-up capital is INR 28.22 cr.
Read more
** All rupee values in INR crores. Based on March 2024 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
State | Type | Address |
---|
Designation | Name | DIN/PAN | Tenure |
---|---|---|---|
Director | Sona Saira Ramasastry | 08398547 | 6 years |
Managing Director | Glenn Mario Saldanha
Shareholder
|
00050607 | 27 years |
Director | Blanche Saldanha Elizabeth
Shareholder
|
00007671 | 16 years |
Whole-time Director | Cherylann Maria Pinto
Shareholder
|
00111844 | 18 years |
Director | Dipankar Bhattacharjee | 08770548 | 5 years |
Director | Rajesh Vasudeo Desai | 00007960 | 8 years |
Director | Vijayalakshmi Iyer | 05242960 | 2 years |
Additional Director | Anurag Mantri | 05326463 | 0 years |
Director | Pradeep Kumar Sinha | 00145126 | 0 years |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Networth | |||||
Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Financials upto March 2024 available in Tofler Pro
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Bank of India
No. of Loans: 1
Total Amount : 890.0 cr
Name | State / Country | Incorporation Year | Paidup Capital |
---|---|---|---|
Glenmark Holding SA | Switzerland | - | - |
Glenmark Pharmaceuticals S.A., Switzerland | Switzerland | - | - |
Glenmark Farmaceutica Ltda. | Brazil | - | - |
Glenmark Pharmaceutical SRO | Czech Republic | - | - |
Glenmark Pharmaceutical SK SRO | Slovakia | - | - |
Glenmark Pharmaceutical SRL | Romania | - | - |
Glenmark Pharmaceuticals (Europe) R&D Ltd. | United Kingdom | - | - |
Glenmark Therapeutics Inc., USA | United States | - | - |
Glenmark Pharmaceuticals SP Z.O.O. | Poland | - | - |
Glenmark-Pharmaceuticals Ecuador S.A. | Ecuador | - | - |
Glenmark South Africa (pty) Ltd | South Africa | - | - |
Glenmark Pharmaceuticals South Africa (pty) Ltd. | South Africa | - | - |
Glenmark Impex L.L.C. | Russian Federation | - | - |
Glenmark Pharmaceuticals (Nigeria) Ltd | Nigeria | - | - |
Glenmark Dominicana SRL | Dominican Republic | - | - |
Glenmark Pharmaceuticals (Australia) Pty Ltd. | Australia | - | - |
Glenmark Pharmaceuticals (Malaysia) SDN.BHD | Malaysia | - | - |
Glenmark Philippines Inc. | Philippines | - | - |
Glenmark Pharmaceuticals Egypt SAE | Egypt | - | - |
Glenmark Pharmaceuticals FZE | United Arab Emirates | - | - |
Glenmark Uruguay SA | Uruguay | - | - |
Glenmark Pharmaceuticals Mexico, S.A DECV. | Mexico | - | - |
Glenmark Pharmaceuticals Peru SAC. | Peru | - | - |
Glenmark Pharmaceuticals Venezuela , CA | Venezuela, Bolivarian Republic Of | - | - |
Glenmark Pharmaceuticals Colombia SAS | Colombia | - | - |
Glenmark Pharmaceuticals Europe Ltd. | United Kingdom | - | - |
Glenmark Pharmaceuticals Inc. USA | United States | - | - |
Glenmark Generics SA Argentina | Argentina | - | - |
Glenmark Pharmaceuticals B.V. | Netherlands | - | - |
Glenmark Arzneimittel GmBH | Germany | - | - |
Glenmark Pharmaceuticals Canada INC | Canada | - | - |
Glenmark Pharmaceuticals (Kenya) Limited | Kenya | - | - |
Glenmark Ttherapeutics AG | Switzerland | - | - |
Glenmark Pharmaceuticals Distribution SRO | Czech Republic | - | - |
Glenmark Specialty SA | Switzerland | - | - |
Viso Farmaceutica SLU | Spain | - | - |
Glenmark Pharmaceuticals (Thailand) Co. Ltd. | Thailand | - | - |
Glenmark Pharmaceuticals Nordic AB | Sweden | - | - |
Glenmark Ukraine LLC | Ukraine | - | - |
Read more
The incorporation date of GLENMARK PHARMACEUTICALS LIMITED is 18 November, 1977
The authorized share capital of GLENMARK PHARMACEUTICALS LIMITED is INR ₹ 277.0 Cr.
The paid-up capital of GLENMARK PHARMACEUTICALS LIMITED is INR ₹ 28.2 Cr.
The registered address of GLENMARK PHARMACEUTICALS LIMITED is B-2MAHALAXMI CHAMBERS22 BHULABHAI DESAI ROAD MAHALAXMI, MUMBAI, Maharashtra, India, 400026 - 400026
The CIN number of GLENMARK PHARMACEUTICALS LIMITED is L24299MH1977PLC019982.